SCHEMBL3843039

SCHEMBL3843039

O=C(Nc1nc2cc(-c3cc(=O)[nH]c(Nc4cccc(O)c4)n3)ccc2[nH]1)c1cccs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
MAPT P10636 8/20 0.42
KMT2A Q03164 5/20 0.42
ALDH1A1 P00352 4/20 0.42
HPGD P15428 3/20 0.42
POLB P06746 2/20 0.42
APAF1 O14727 2/20 0.42
PPARG P37231 1/20 0.42
RECQL P46063 1/20 0.42
SMAD3 P84022 1/20 0.42
PTK2B Q14289 1/20 0.42
ESR2 Q92731 1/20 0.42
NR2E3 Q9Y5X4 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
MEN1 O00255 4/20 0.40
VSIR Q9H7M9 3/20 0.40
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14513944 0.93 KDM4E (0.52) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3842188 0.92 KDM4E (0.57) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3843297 0.90 KDM4E (0.53) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3845531 0.89 RAB9A (0.51) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL5632430 0.89 KDM4E (0.47) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3852878 0.86 RAB9A (0.48) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL4369148 0.86 RAB9A (0.49) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL14513945 0.85 KDM4E (0.57) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3844820 0.84 KDM4E (0.53) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3903906 0.84 SMN1; SMN2 (0.53) KDM4ESMN1; SMN2RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713793-A4 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-09-02 EP claimed
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HASEGAWA MASAICHI 2007-05-24 US claimed
EP-1713793-A2 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS Smithkline Beecham Corporation (US) 2006-10-25 EP claimed
WO-2005076854-A2 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO claimed
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HASEGAWA MASAICHI 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HIPK3, HIPK1, HIPK2 KDM4E 1975/4885SMN1; SMN2 1981/4885RAB9A 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.